gainbot
BriefMoversScreensSectorsEarningsIPOsNewsDividends & splitsScreenerWatchlistLearn
NASDAQ · LNTHHealthcareDiagnostics

Lantheus Holdings, Inc (LNTH)

$101.14+0.34%
Close Nov 4, 2026 · split-adjusted
Nov 3, 2026$100.80▲ 77.40% in range
Nov 3, 2025Low $50.69 · High $110.94Nov 3, 2026
What changed · written from our data
As of Nov 4, 2026

Lantheus Holdings closed at $101.14 on Nov 4, up 0.34%, 8.8% below its 52-week closing high. Volume of 1.1M shares was 1.07× its 20-day average (close to normal).

Split-adjusted performance: +1.2% over one month, +17.4% over six months, +78.0% over one year.

In the quarter ended Jun 30, 2026, revenue was $388.18M, up 2.7% from a year earlier, with a net margin of 19.3%.

Short interest was 3.6M shares at the Oct 15 settlement, down 4.0% from the prior report (5.7% of float, 4.5 days to cover).

Market cap$6.60B65.3M shares
Revenue · quarter$388.2M+2.7% YoY
Diluted EPS$1.11−0.9% YoY
P/E · TTM24.0×P/S 4.2×
Net margin19.3%Gross 62.3%
Dividend yieldNone
52-week range50.69 – 110.94−8.8% from high
Volume1.1M1.07× 20-day avg
Volatility · 60d4.1%Annualised
Short % of float5.7%4.5 days to cover
Net cash$22.2MCash $593.3M
Next earnings—Not scheduled
Split-adjusted performance
1W +1.0%1M +1.2%3M +0.1%6M +17.4%YTD +52.0%1Y +78.0%3Y +64.2%5Y +348.7%

Earnings reactions

History →

No reported quarters with price history yet.

Rank within Diagnostics

Percentile among 15 companies (100 = best)

6-month momentum50
Revenue growth58
Net margin83
Value (low P/E)—
Size93

Industry medians: 6-month return +17.4%, revenue growth −2.0%, net margin −26.0%, P/E 46.6×.

Short interest

Details →
Shares short3.6M−4.0% vs prior
Days to cover4.5Settled Oct 15
% of float5.7%
Short vol. 10d46.0%of daily volume

Closest peers by size in Diagnostics

CompanyPriceToday6MRev. growthNet marginP/EMkt cap
LNTHLantheus Holdings$101.14+0.34%+17.4%+2.7%19.3%24.0$6.60B
NEOGNeogen$12.46+2.98%+35.7%+6.5%−5.3%—$2.72BCompare
CLDXCelldex Therapeutics$29.93+0.74%−13.0%−97.0%−334104.5%—$2.35BCompare
NTLAIntellia Therapeutics$12.31+3.79%−11.1%−46.2%−1392.3%—$1.72BCompare
QDELQuidelOrtho$14.35+1.85%+30.9%+2.8%−14.7%—$984.1MCompare
IDXXIdexx Laboratories$698.55+3.94%+20.6%+9.9%26.1%46.6$55.03BCompare
ACHVAchieve Life Sciences$6.98+3.71%+45.4%———$719.7MCompare
MYGNMyriad Genetics$6.02−0.33%+46.5%−10.5%−22.7%—$575.8MCompare
TKNOAlpha Teknova$7.37+0.41%+102.5%+18.5%−26.0%—$454.7MCompare

News about Lantheus Holdings

All news →
Halper Sadeh LLC is Investigating Whether ITGR, FHB, INDV, LNTH are Obtaining Fair Deals for their ShareholdersGlobeNewswire Inc. · Sep 30, 2026▼ NegativeCurium™ announces FDA approval of BEXLUTRY lutetium Lu 177 dotatate injection for adults with SSTR-positive GEP-NETsGlobeNewswire Inc. · Sep 14, 2026▲ PositiveHalper Sadeh LLC is Investigating Whether MKTX, SMTI, LNTH are Obtaining Fair Deals for their ShareholdersGlobeNewswire Inc. · Aug 4, 2026▼ NegativeCurium Announces Definitive Agreement to Merge with LantheusGlobeNewswire Inc. · Aug 3, 2026▲ PositiveLantheus Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business UpdateGlobeNewswire Inc. · Feb 26, 2026Neutral

Quick answers

What does Lantheus Holdings do?
Lantheus Holdings Inc is a radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver patient outcomes. The Company classifies its products into Radiopharmaceutical Oncology, Precision Diagnostics, and Strategic Partnerships and Other Revenue.
What is LNTH's market cap?
$6.60B, based on the Nov 4 close of $101.14.
What is LNTH's P/E ratio?
24.0× trailing-twelve-month earnings of $275.31M.
Does Lantheus Holdings pay a dividend?
No regular cash dividend has been paid in the last year.
How much of LNTH is sold short?
3.6M shares, 5.7% of float, as of Oct 15, 2026.
What sector is LNTH in?
Healthcare, in the Diagnostics industry.

About Lantheus Holdings

Lantheus Holdings Inc is a radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver patient outcomes. The Company classifies its products into Radiopharmaceutical Oncology, Precision Diagnostics, and Strategic Partnerships and Other Revenue. Its products help healthcare professionals Find, Fight and Follow cancer and diseases and are used by physicians and technologists in clinical settings. The Company produces and markets its products in the United States, mainly to hospitals, independent imaging centers and government facilities, and sells outside the United States through direct and third-party distribution relationships and licensing arrangements in Europe, Canada, Australia, Asia-Pacific, Central America and South America.

HQ: North Billerica, MA1,193 employeesListed Jun 25, 2015lantheus.com

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology